Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Hemorphin-4

From Wikipedia, the free encyclopedia
Endogenous opioid peptide
Hemorphin-4
Names
IUPAC name
(2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoic acid
Other names
L-tyrosyl-L-prolyl-L-tryptophyl-L-threonine
Identifiers
3D model (JSmol)
ChemSpider
  • InChI=1S/C29H35N5O7/c1-16(35)25(29(40)41)33-26(37)23(14-18-15-31-22-6-3-2-5-20(18)22)32-27(38)24-7-4-12-34(24)28(39)21(30)13-17-8-10-19(36)11-9-17/h2-3,5-6,8-11,15-16,21,23-25,31,35-36H,4,7,12-14,30H2,1H3,(H,32,38)(H,33,37)(H,40,41)/t16-,21+,23+,24+,25+/m1/s1
    Key: WEGGKZQIJMQCGR-RECQUVTISA-N
  • C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](Cc4ccc(cc4)O)N)O
Properties
C29H35N5O7
Molar mass565.618 g/mol
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa).
Chemical compound

Hemorphin-4 is anendogenousopioid peptide of thehemorphin family which possessesantinociceptive properties and is derived from the β-chain ofhemoglobin in the bloodstream.[1][2] It contains atetrapeptide core with theamino acid sequence Tyr-Pro-Trp-Thr. Hemorphin-4 serves as a opioid receptor ligand that hasaffinities for theμ-,δ-, andκ-opioid receptors in the same range as the structurally relatedβ-casomorphins, although affinity to the κ-opioid receptor is markedly higher in comparison.[3] It acts as anagonist at these sites.[4] It presents high affinity for other receptors such as angiotensin IV, bombesin subtype 3 (hBRS-3), and thecorticotropin releasing factor (CRF).[5] Even though it exhibits lower binding affinity for opioid receptors relative to traditional opioid peptides such asendorphins andenkephalins; it may still influence opioid receptor systems due to its high tissue concentration.

Therapeutic potentials

[edit]

Hemorphin-4 also hasinhibitory effects onangiotensin-converting enzyme (ACE),[6] and as a result, may play a role in the regulation ofblood pressure.[3] Notably, inhibition of ACE also reducesenkephalincatabolism.[7] Upon modifications withadamantane andcyclohexane, the Hemorphin-4 analog inhibitsinsulin-regulated aminopeptidase (IRAP) compared to other angiotensin IV inhibitors, making it a suitable candidate for pain, anxiety, and depression therapies.[5] In binding to the μ-opioid receptor, it has significant seizure-suppressing and pain-relieving properties and reduces involuntary bladder contractions in a similar manner to classic opioids.[8]

See also

[edit]

References

[edit]
  1. ^Brantl V, Gramsch C, Lottspeich F, Mertz R, Jaeger KH, Herz A (June 1986). "Novel opioid peptides derived from hemoglobin: hemorphins".European Journal of Pharmacology.125 (2):309–10.doi:10.1016/0014-2999(86)90044-0.PMID 3743640.
  2. ^Davis TP, Gillespie TJ, Porreca F (1989). "Peptide fragments derived from the beta-chain of hemoglobin (hemorphins) are centrally active in vivo".Peptides.10 (4):747–51.doi:10.1016/0196-9781(89)90107-1.PMID 2587417.S2CID 11168006.
  3. ^abLiebmann C, Schrader U, Brantl V (August 1989). "Opioid receptor affinities of the blood-derived tetrapeptides hemorphin and cytochrophin".European Journal of Pharmacology.166 (3):523–6.doi:10.1016/0014-2999(89)90368-3.PMID 2553436.
  4. ^Erchegyi J, Kastin AJ, Zadina JE (1992). "Isolation of a novel tetrapeptide with opiate and antiopiate activity from human brain cortex: Tyr-Pro-Trp-Gly-NH2 (Tyr-W-MIF-1)".Peptides.13 (4):623–31.doi:10.1016/0196-9781(92)90165-Y.PMID 1359507.S2CID 32330624.
  5. ^abMielczarek, Przemyslaw; Hartman, Kinga; Drabik, Anna; Hung, Hao-Yuan; Huang, Eagle Yi-Kung; Gibula-Tarlowska, Ewa; Kotlinska, Jolanta H.; Silberring, Jerzy (2021-06-25)."Hemorphins—From Discovery to Functions and Pharmacology".Molecules.26 (13): 3879.doi:10.3390/molecules26133879.ISSN 1420-3049.PMC 8270332.PMID 34201982.
  6. ^Lantz I, Glämsta EL, Talbäck L, Nyberg F (August 1991). "Hemorphins derived from hemoglobin have an inhibitory action on angiotensin converting enzyme activity".FEBS Letters.287 (1–2):39–41.Bibcode:1991FEBSL.287...39L.doi:10.1016/0014-5793(91)80011-Q.PMID 1652464.S2CID 26892050.
  7. ^Benuck M, Berg MJ, Marks N (1982). "Separate metabolic pathways for Leu-enkephalin and Met-enkephalin-Arg(6)-Phe(7) degradation by rat striatal synaptosomal membranes".Neurochemistry International.4 (5):389–96.doi:10.1016/0197-0186(82)90081-X.PMID 20487892.S2CID 23138078.
  8. ^Ali, Amanat; Alzeyoudi, Seham Abdullah Rashed; Almutawa, Shamma Abdulla; Alnajjar, Alya Nasir; Vijayan, Ranjit (2020-08-01)."Molecular basis of the therapeutic properties of hemorphins".Pharmacological Research.158 104855.doi:10.1016/j.phrs.2020.104855.ISSN 1043-6618.PMID 32438036.
Hormones
Opioid peptides
Dynorphins
Endomorphins
Endorphins
Enkephalins
Others
Other
neuropeptides
Kinins
Neuromedins
Orexins
Other
μ-opioid
(MOR)
Agonists
(abridged;
full list)
Antagonists
δ-opioid
(DOR)
Agonists
Antagonists
κ-opioid
(KOR)
Agonists
Antagonists
Nociceptin
(NOP)
Agonists
Antagonists
Others


Stub icon

Thisbiochemistry article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Hemorphin-4&oldid=1314089349"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp